ImmunityBio (NASDAQ:IBRX) Trading 13% Higher After Earnings Beat

ImmunityBio, Inc. (NASDAQ:IBRX)’s share price rose 13% during mid-day trading on Monday following a better than expected earnings announcement. The company traded as high as $11.00 and last traded at $9.83. Approximately 85,988,851 shares changed hands during trading, an increase of 95% from the average daily volume of 44,149,879 shares. The stock had previously closed at $8.70.

The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

Wall Street Analyst Weigh In

A number of equities research analysts have commented on IBRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday. BTIG Research lifted their price target on shares of ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group upped their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a report on Monday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Insider Buying and Selling

In other ImmunityBio news, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This trade represents a 5.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Christobel Selecky sold 50,000 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold 426,967 shares of company stock valued at $3,565,662 in the last 90 days. Company insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its position in ImmunityBio by 193.4% in the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after purchasing an additional 29,297 shares in the last quarter. CWM LLC increased its stake in shares of ImmunityBio by 849.2% during the second quarter. CWM LLC now owns 48,715 shares of the company’s stock worth $129,000 after buying an additional 43,583 shares during the period. Dillon & Associates Inc. acquired a new stake in ImmunityBio in the second quarter valued at approximately $68,000. Rathbones Group PLC lifted its stake in ImmunityBio by 21.5% in the second quarter. Rathbones Group PLC now owns 117,420 shares of the company’s stock worth $310,000 after acquiring an additional 20,800 shares during the last quarter. Finally, Summit X LLC purchased a new position in ImmunityBio in the second quarter worth approximately $28,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Trading Up 17.5%

The firm’s fifty day simple moving average is $4.82 and its 200 day simple moving average is $3.24. The company has a market cap of $11.38 billion, a price-to-earnings ratio of -30.39 and a beta of 0.16.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.